See more : Beijing Airport High-Tech Park Co., Ltd. (600463.SS) Income Statement Analysis – Financial Results
Complete financial analysis of AVEO Pharmaceuticals, Inc. (AVEO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AVEO Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Alaska Communications Systems Group, Inc. (ALSK) Income Statement Analysis – Financial Results
- Griptha Putra Persada Tbk. (GRPH.JK) Income Statement Analysis – Financial Results
- Anson Resources Limited (ANSNF) Income Statement Analysis – Financial Results
- Companhia Energética do Rio Grande do Norte – COSERN (CSRN6.SA) Income Statement Analysis – Financial Results
- Brookfield Infrastructure Corpo (BIPH) Income Statement Analysis – Financial Results
AVEO Pharmaceuticals, Inc. (AVEO)
About AVEO Pharmaceuticals, Inc.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC, HCC, immunologically cold tumors, and CCA. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; and AstraZeneca PLC. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 38.87M | 6.02M | 28.80M | 5.41M | 7.58M | 2.52M | 19.02M | 18.12M | 1.29M | 19.29M | 164.85M | 44.68M | 20.72M | 19.66M | 11.03M |
| Cost of Revenue | 4.74M | 1.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 34.14M | 4.77M | 28.80M | 5.41M | 7.58M | 2.52M | 19.02M | 18.12M | 1.29M | 19.29M | 164.85M | 44.68M | 20.72M | 19.66M | 11.03M |
| Gross Profit Ratio | 87.81% | 79.32% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 26.30M | 22.68M | 17.96M | 20.65M | 25.18M | 23.70M | 12.88M | 38.25M | 68.47M | 91.36M | 101.74M | 86.35M | 51.79M | 41.82M | 29.25M |
| General & Administrative | 0.00 | 22.22M | 11.21M | 10.78M | 9.14M | 8.21M | 14.22M | 18.59M | 28.71M | 36.93M | 29.17M | 14.76M | 10.12M | 9.16M | 6.50M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 60.81M | 22.22M | 11.21M | 10.78M | 9.14M | 8.21M | 14.22M | 18.59M | 28.71M | 36.93M | 29.17M | 14.76M | 10.12M | 9.16M | 6.50M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.36M | 11.73M | 8.02M | 2.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 87.11M | 44.90M | 29.17M | 31.43M | 34.32M | 31.91M | 27.09M | 56.84M | 97.18M | 128.29M | 130.90M | 101.11M | 61.91M | 50.99M | 35.75M |
| Cost & Expenses | 91.85M | 44.90M | 29.17M | 31.43M | 34.32M | 31.91M | 27.09M | 56.84M | 97.18M | 128.29M | 130.90M | 101.11M | 61.91M | 50.99M | 35.75M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 21.00K | 32.00K | 125.00K | 497.00K | 527.00K | 126.00K | 144.26K | 1.17M | 2.17M |
| Interest Expense | -4.05M | 1.61M | 1.82M | 2.19M | 2.37M | 1.95M | 2.31M | 2.39M | 3.13M | 3.50M | 3.84M | 3.39M | 2.81M | 2.09M | 2.44M |
| Depreciation & Amortization | -7.83M | 21.00K | 11.58M | 22.22M | -33.74M | 30.00K | 9.57M | 6.22M | 3.78M | 2.51M | 1.65M | 1.35M | 1.29M | 1.32M | 1.33M |
| EBITDA | -57.39M | -33.96M | 11.20M | -3.14M | -62.55M | -24.81M | -3.13M | -44.13M | -100.13M | -108.38M | 36.14M | -54.05M | -40.09M | -29.07M | -21.21M |
| EBITDA Ratio | -147.62% | -564.18% | 38.91% | -58.01% | -825.32% | -986.36% | -16.44% | -243.51% | -7,743.77% | -561.98% | 21.92% | -120.97% | -193.52% | -147.84% | -192.22% |
| Operating Income | -49.55M | -38.88M | -374.00K | -25.36M | -28.81M | -29.39M | -12.43M | -50.45M | -103.90M | -111.64M | 33.95M | -56.43M | -41.19M | -31.33M | -24.72M |
| Operating Income Ratio | -127.47% | -645.90% | -1.30% | -468.79% | -380.14% | -1,168.71% | -65.32% | -278.37% | -8,035.89% | -578.85% | 20.59% | -126.28% | -198.83% | -159.33% | -223.99% |
| Total Other Income/Expenses | -3.79M | 3.29M | 9.76M | 20.03M | -36.11M | 2.61M | -2.58M | -2.29M | -3.13M | -2.76M | -3.30M | -2.36M | -3.00M | -1.15M | -266.03K |
| Income Before Tax | -53.34M | -35.58M | 9.39M | -5.33M | -64.92M | -26.79M | -15.00M | -52.74M | -107.03M | -114.39M | 30.65M | -58.79M | -44.19M | -32.47M | -24.98M |
| Income Before Tax Ratio | -137.22% | -591.19% | 32.60% | -98.52% | -856.63% | -1,065.05% | -78.85% | -291.01% | -8,277.57% | -593.15% | 18.59% | -131.57% | -213.30% | -165.17% | -226.40% |
| Income Tax Expense | 7.83M | 4.90M | 0.00 | 0.00 | 101.00K | 101.00K | -268.00K | 98.00K | 2.00K | 744.00K | 537.00K | 1.03M | -100.06K | 937.81K | 2.17M |
| Net Income | -61.18M | -35.58M | 9.39M | -5.33M | -65.03M | -26.89M | -15.00M | -52.74M | -107.03M | -114.39M | 30.65M | -58.79M | -44.09M | -32.47M | -24.98M |
| Net Income Ratio | -157.37% | -591.19% | 32.60% | -98.52% | -857.96% | -1,069.07% | -78.85% | -291.01% | -8,277.57% | -593.15% | 18.59% | -131.57% | -212.82% | -165.17% | -226.40% |
| EPS | -2.86 | -1.66 | 0.61 | -0.41 | -6.14 | -3.88 | -2.69 | -10.09 | -21.02 | -26.37 | 7.72 | -22.98 | -22.31 | -202.07 | -155.46 |
| EPS Diluted | -2.86 | -1.66 | 0.61 | -0.41 | -6.14 | -3.88 | -2.69 | -10.09 | -21.02 | -26.37 | 7.39 | -22.98 | -22.31 | -202.07 | -155.46 |
| Weighted Avg Shares Out | 21.40M | 21.40M | 15.38M | 13.07M | 10.59M | 6.93M | 5.57M | 5.23M | 5.09M | 4.34M | 3.97M | 2.56M | 1.98M | 160.70K | 160.70K |
| Weighted Avg Shares Out (Dil) | 21.40M | 21.40M | 15.38M | 13.07M | 10.59M | 6.93M | 5.57M | 5.23M | 5.09M | 4.34M | 4.15M | 2.56M | 1.98M | 160.70K | 160.70K |
AVEO Oncology Reports Full Year 2020 Financial Results and Provides Business Update
AVEO Collaborates with Bristol Myers to Conduct Combo Study
AVEO Pharmaceuticals, CANbridge AV-203 Licensing Deal Axed, AVEO Regains Ex-North American Rights
AVEO Stock Price Increases Over 5% Pre-Market: Why It Happened
AVEO Oncology Announces Collaboration with Bristol Myers Squibb to Evaluate FOTIVDA® (tivozanib) in Combination with OPDIVO® (nivolumab) in Pivotal Phase 3 TiNivo-2 Trial in IO Relapsed Renal Cell Carcinoma
AVEO Oncology Announces Drawdown of $20 Million Tranche Under Hercules Debt Facility
Aveo Pharmaceuticals Stock Volatile After FDA Approval: Technical Levels To Watch
Aveo extends gains to 106% after drug maker wins FDA approval for kidney cancer treatment (AVEO)
Aveo Pharma's Stock Trading Higher On Much Awaited FDA Approval For Tivozanib In Relapsed Kidney Cancer
AVEO Stock Price Increases Over 20% Pre-Market: Why It Happened
Source: https://incomestatements.info
Category: Stock Reports